Jump Financial LLC Takes Position in Janux Therapeutics, Inc. $JANX

Key Points

• Jump Financial LLC has acquired a new stake in Janux Therapeutics, Inc., buying 94,030 shares valued at approximately $2.54 million, representing 0.16% of the company.
• Several other major investors, including Price T Rowe Associates and Aberdeen Group plc, have significantly increased their positions in Janux, which now sees institutional ownership at 75.39%.
• Janux Therapeutics recently missed earnings expectations, reporting a loss of ($0.55) per share, with analysts forecasting a consensus target price of $86.90 and a "Buy" rating for the stock.

Jump Financial LLC bought a new stake in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 94,030 shares of the company's stock, valued at approximately $2,539,000. Jump Financial LLC owned 0.16% of Janux Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently bought and sold shares of the company. Price T Rowe Associates Inc. MD boosted its holdings in shares of Janux Therapeutics by 25.5% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,392,826 shares of the company's stock valued at $37,607,000 after purchasing an additional 282,848 shares during the last quarter. Erste Asset Management GmbH purchased a new position in shares of Janux Therapeutics in the 1st quarter worth $786,000. Aberdeen Group plc boosted its holdings in Janux Therapeutics by 250.8% in the first quarter. Aberdeen Group plc now owns 224,788 shares of the company's stock valued at $6,069,000 after acquiring an additional 160,716 shares during the last quarter. E Fund Management Co. Ltd. boosted its holdings in Janux Therapeutics by 6.3% in the first quarter. E Fund Management Co. Ltd. now owns 68,644 shares of the company's stock valued at $1,853,000 after acquiring an additional 4,076 shares during the last quarter. Finally, Russell Investments Group Ltd. grew its position in Janux Therapeutics by 15,117.4% during the first quarter. Russell Investments Group Ltd. now owns 153,848 shares of the company's stock valued at $4,154,000 after acquiring an additional 152,837 shares during the period. Hedge funds and other institutional investors own 75.39% of the company's stock.

Janux Therapeutics Price Performance

Shares of JANX opened at $23.64 on Wednesday. The stock's 50-day moving average is $24.52 and its two-hundred day moving average is $27.44. The stock has a market cap of $1.42 billion, a PE ratio of -13.13 and a beta of 2.86. Janux Therapeutics, Inc. has a 12 month low of $21.97 and a 12 month high of $71.71.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.07). On average, research analysts anticipate that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current year.

Wall Street Analysts Forecast Growth

JANX has been the topic of a number of research reports. Raymond James Financial initiated coverage on Janux Therapeutics in a report on Friday, July 11th. They issued an "outperform" rating and a $65.00 price objective on the stock. Piper Sandler began coverage on shares of Janux Therapeutics in a research report on Monday, August 18th. They set an "overweight" rating and a $42.00 target price for the company. Two investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Hold rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $86.90.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.